{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:27:00Z","timestamp":1789421220257,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with type 2 diabetes mellitus (T2DM) are prone to develop non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). We aimed to investigate whether the resveratrol supplementation improves novel hepatic and cardiovascular indices in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a double-blind, randomized controlled trial for 8\u00a0weeks. Seventy-six patients with T2DM were randomly assigned to receive 1000\u00a0mg\/day resveratrol or placebo. Levels of lipid accumulation product (LAP), visceral adiposity index (VAI), Castelli risk index I (CRI-I), CRI-II and atherogenic coefficient (AC) were measured at the beginning and after intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 71 participants completed the trial. After adjusting for confounding factors including medications, diabetes duration, energy intake and physical activity, no significant difference was found between the intervention group and the control group in LAP (mean change: \u2212\u20092.46\u2009\u00b1\u200923.3 vs. 1.43\u2009\u00b1\u200914.3; P\u2009=\u20090.43), VAI (mean change: \u2212\u20090.25\u2009\u00b1\u20091.1 vs. \u2212\u20090.02\u2009\u00b1\u20090.6; P\u2009=\u20090.47), CRI-I (mean change: \u2212\u20090.25\u2009\u00b1\u20090.9 vs. \u2212\u20090.09\u2009\u00b1\u20090.5; P\u2009=\u20090.79), CRI-II (mean change: \u2212\u20090.23\u2009\u00b1\u20090.7 vs. \u2212\u20090.06\u2009\u00b1\u20090.6; P\u2009=\u20090.38) and AC (mean change: \u2212\u20090.25\u2009\u00b1\u20090.9 vs. \u2212\u20090.09\u2009\u00b1\u20090.5; P\u2009=\u20090.79).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Resveratrol supplementation had no effect on hepatic steatosis and cardiovascular indices. Further clinical trials, especially among subjects with dyslipidemia are needed to reach a firm conclusion. In addition, taking all medications should be controlled in future studies.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> The protocol was registered on 29\/12\/2017 at the Iranian clinical trials website (IRCT20171118037528N1) with URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/trial\/27734\">https:\/\/en.irct.ir\/trial\/27734<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02637-2","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T07:02:59Z","timestamp":1652166179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Abbas","family":"Ali Sangouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-1778","authenticated-orcid":false,"given":"Hassan","family":"Mozaffari-Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"issue":"3","key":"2637_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"DR Whiting","year":"2011","unstructured":"Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311\u201321.","journal-title":"Diabetes Res Clin Pract"},{"key":"2637_CR2","first-page":"107","volume":"10","author":"M Abdul","year":"2020","unstructured":"Abdul M, Khan B, Hashim MJ, King JK, Govender RD, Mustafa H, et al. Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107\u201311.","journal-title":"J Epidemiol Glob Health"},{"issue":"Suppl 1","key":"2637_CR3","first-page":"S67","volume":"36","author":"AA Diabetes","year":"2010","unstructured":"Diabetes AA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;36(Suppl 1):S67-74.","journal-title":"Diabetes Care"},{"issue":"26","key":"2637_CR4","doi-asserted-by":"publisher","first-page":"8377","DOI":"10.3748\/wjg.v20.i26.8377","volume":"20","author":"NC Leite","year":"2014","unstructured":"Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20(26):8377\u201392.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2637_CR5","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100(6):2231\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2637_CR6","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.dsx.2019.05.013","volume":"13","author":"AA Sangouni","year":"2019","unstructured":"Sangouni AA, Ghavamzadeh S, Jamalzehi A. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Clin Res Rev. 2019;13(3):2260\u20135.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"5","key":"2637_CR7","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1016\/j.dsx.2019.07.063","volume":"13","author":"AA Sangouni","year":"2019","unstructured":"Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr Clin Res Rev. 2019;13(5):2917\u201322.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"17","key":"2637_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):1\u201334.","journal-title":"Int J Mol Sci"},{"key":"2637_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-230X-10-98","volume":"10","author":"G Bedogni","year":"2010","unstructured":"Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2637_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2337\/dc09-1825","volume":"33","author":"MC Amato","year":"2010","unstructured":"Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920\u20132.","journal-title":"Diabetes Care"},{"key":"2637_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.11.023","author":"AA Sangouni","year":"2021","unstructured":"Sangouni AA, Sangsefidi ZS, Yarhosseini F, Hosseinzadeh M, Akhondi-Meybodi M, Ranjbar A, et al. Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled trial. Clin Nutr ESPEN. 2021. https:\/\/doi.org\/10.1016\/j.clnesp.2021.11.023.","journal-title":"Clin Nutr ESPEN"},{"key":"2637_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clnesp.2021.06.015","volume":"44","author":"AA Sangouni","year":"2021","unstructured":"Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. Clin Nutr ESPEN. 2021;44:130\u20135.","journal-title":"Clin Nutr ESPEN"},{"key":"2637_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clnesp.2021.08.005","volume":"46","author":"AA Sangouni","year":"2021","unstructured":"Sangouni AA, Sasanfar B, Ghadiri-Anari A, Hosseinzadeh M. Effect of L-carnitine supplementation on liver fat content and cardiometabolic indices in overweight\/obese women with polycystic ovary syndrome: a randomized controlled trial. Clin Nutr ESPEN. 2021;46:54\u20139.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"2637_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):1\u201319.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2637_CR15","first-page":"78","volume":"16","author":"R Sujatha","year":"2017","unstructured":"Sujatha R, Kavitha S. Atherogenic indices in stroke patients: a retrospective study. Iran J Neurol. 2017;16(2):78\u201382.","journal-title":"Iran J Neurol"},{"issue":"2","key":"2637_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.18231\/j.ijcbr.2020.055","volume":"7","author":"T Sasikala","year":"2020","unstructured":"Sasikala T, Goswami K. Castelli risk index-1 and atherogenic coefficient are better predictors of cardiometabolic risk in patients with hypothyroidism. Int J Clin Biochem Res. 2020;7(2):254\u20139.","journal-title":"Int J Clin Biochem Res"},{"issue":"11","key":"2637_CR17","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1021\/jf0112973","volume":"50","author":"J Burns","year":"2002","unstructured":"Burns J, Yokota T, Ashihara H, Lean MEJ, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50(11):3337\u201340.","journal-title":"J Agric Food Chem"},{"issue":"3","key":"2637_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S0007114511000316","volume":"106","author":"P Brasny\u00f3","year":"2011","unstructured":"Brasny\u00f3 P, Moln\u00e1r GA, Moh\u00e1s M, Mark\u00f3 L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383\u20139.","journal-title":"Br J Nutr"},{"issue":"1","key":"2637_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-017-0217-z","volume":"14","author":"X Zhu","year":"2017","unstructured":"Zhu X, Wu C, Qiu S, Yuan X, Li L. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab. 2017;14(1):1\u201310.","journal-title":"Nutr Metab"},{"issue":"8","key":"2637_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/ptr.6655","volume":"34","author":"M Tabatabaie","year":"2020","unstructured":"Tabatabaie M, Abdollahi S, Salehi-Abargouei A, Clark CCT, Karimi-Nazari E, Fallahzadeh H, et al. The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: a randomized, double-blind controlled trial. Phyther Res. 2020;34(8):2023\u201331.","journal-title":"Phyther Res"},{"issue":"11","key":"2637_CR21","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jnutbio.2015.06.006","volume":"26","author":"PK Bagul","year":"2015","unstructured":"Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem. 2015;26(11):1298\u2013307.","journal-title":"J Nutr Biochem"},{"issue":"10","key":"2637_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","volume":"34","author":"F Faghihzadeh","year":"2014","unstructured":"Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837\u201343.","journal-title":"Nutr Res"},{"issue":"1","key":"2637_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12986-017-0183-5","volume":"14","author":"R Sharma","year":"2017","unstructured":"Sharma R, Sharma NK, Thungapathra M. Resveratrol regulates body weight in healthy and ovariectomized rats. Nutr Metab. 2017;14(1):4\u20139.","journal-title":"Nutr Metab"},{"issue":"7","key":"2637_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jsps.2019.08.006","volume":"27","author":"A Ra\u0161kovi\u0107","year":"2019","unstructured":"Ra\u0161kovi\u0107 A, \u0106u\u0107uz V, Torovi\u0107 L, Tomas A, Gojkovi\u0107-Bukarica L, \u0106ebovi\u0107 T, et al. Resveratrol supplementation improves metabolic control in rats with induced hyperlipidemia and type 2 diabetes. Saudi Pharm J. 2019;27(7):1036\u201343.","journal-title":"Saudi Pharm J"},{"issue":"2","key":"2637_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1017\/S0007114511002753","volume":"107","author":"S G\u00f3mez-Zorita","year":"2012","unstructured":"G\u00f3mez-Zorita S, Fern\u00e1ndez-Quintela A, MacArulla MT, Aguirre L, Hijona E, Bujanda L, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012;107(2):202\u201310.","journal-title":"Br J Nutr"},{"issue":"6","key":"2637_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jhep.2008.08.012","volume":"49","author":"J Ahn","year":"2008","unstructured":"Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol. 2008;49(6):1019\u201328.","journal-title":"J Hepatol"},{"key":"2637_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-8-40","volume":"8","author":"L Bujanda","year":"2008","unstructured":"Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garc\u00eda-Urkia N, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008;8:1\u20138.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2637_CR28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.2337\/db12-0975","volume":"62","author":"MM Poulsen","year":"2013","unstructured":"Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, St\u00f8dkilde-J\u00f8rgensen H, et al. High-dose resveratrol supplementation in obese men an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62(4):1186\u201395.","journal-title":"Diabetes"},{"issue":"12","key":"2637_CR29","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1002\/ptr.6487","volume":"33","author":"S Abdollahi","year":"2019","unstructured":"Abdollahi S, Salehi-Abargouei A, Toupchian O, Sheikhha MH, Fallahzadeh H, Rahmanian M, et al. The effect of resveratrol supplementation on cardio-metabolic risk factors in patients with type 2 diabetes: a randomized, double-blind controlled trial. Phyther Res. 2019;33(12):3153\u201362.","journal-title":"Phyther Res"},{"issue":"9","key":"2637_CR30","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1039\/C9FO01075K","volume":"10","author":"A Hoseini","year":"2019","unstructured":"Hoseini A, Namazi G, Farrokhian A, Reiner \u017d, Aghadavod E, Bahmani F, et al. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food Funct. 2019;10(9):6042\u201351.","journal-title":"Food Funct"},{"issue":"12","key":"2637_CR31","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","volume":"12","author":"VS Chachay","year":"2014","unstructured":"Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O\u2019Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092-2103.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2637_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0007114515002433","volume":"114","author":"F Faghihzadeh","year":"2015","unstructured":"Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796\u2013803.","journal-title":"Br J Nutr"},{"issue":"10","key":"2637_CR33","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1111\/dom.13409","volume":"20","author":"MK Poulsen","year":"2018","unstructured":"Poulsen MK, Nellemann B, Bibby BM, St\u00f8dkilde-J\u00f8rgensen H, Pedersen SB, Gr\u00f8nb\u00e6k H, et al. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes Obes Metab. 2018;20(10):2504\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2637_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-026337","volume":"9","author":"S Abdollahi","year":"2019","unstructured":"Abdollahi S, Salehi-Abargouei A, Tabatabaie M, Sheikhha MH, Fallahzadeh H, Rahmanian M, et al. The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163\/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial. BMJ Open. 2019;9(7):1\u20136.","journal-title":"BMJ Open"},{"issue":"12","key":"2637_CR35","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.bbadis.2013.09.006","volume":"1832","author":"S D\u2019Amore","year":"2013","unstructured":"D\u2019Amore S, Vacca M, Graziano G, D\u2019Orazio A, Cariello M, Martelli N, et al. Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome. Biochim Biophys Acta Mol Basis Dis. 2013;1832(12):2289\u2013301.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5","key":"2637_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5694\/j.1326-5377.2002.tb04759.x","volume":"177","author":"A Kirby","year":"2002","unstructured":"Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Med J Aust. 2002;177(5):256\u20137.","journal-title":"Med J Aust"},{"key":"2637_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2288-4-26","volume":"4","author":"M Saghaei","year":"2004","unstructured":"Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004;4:26.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2637_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1006\/jfca.1999.0867","volume":"13","author":"PR Pehrsson","year":"2000","unstructured":"Pehrsson PR, Haytowitz DB, Holden JM, Perry CR, Beckler DG. USDA\u2019s national food and nutrient analysis program: food sampling. J Food Compos Anal. 2000;13(4):379\u201389.","journal-title":"J Food Compos Anal"},{"issue":"7","key":"2637_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1249\/01.MSS.0000074446.02192.14","volume":"35","author":"M Aadahl","year":"2003","unstructured":"Aadahl M, J\u00f8rgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003;35(7):1196\u2013202.","journal-title":"Med Sci Sports Exerc"},{"issue":"12","key":"2637_CR40","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/dc16-0499","volume":"39","author":"S Timmers","year":"2016","unstructured":"Timmers S, De Ligt M, Phielix E, Van De Weijer T, Hansen J, Moonen-Kornips E, et al. Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial. Diabetes Care. 2016;39(12):2211\u20137.","journal-title":"Diabetes Care"},{"issue":"6","key":"2637_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1745-7254.2008.00807.x","volume":"29","author":"J Shang","year":"2008","unstructured":"Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin. 2008;29(6):698\u2013706.","journal-title":"Acta Pharmacol Sin"},{"issue":"3\u20134","key":"2637_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1024\/0300-9831\/a000528","volume":"90","author":"L Farzin","year":"2020","unstructured":"Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90(3\u20134):279\u201389.","journal-title":"Int J Vitam Nutr Res"},{"key":"2637_CR43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","volume":"111","author":"S Bo","year":"2016","unstructured":"Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016;111:896\u2013905.","journal-title":"Pharmacol Res"},{"key":"2637_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nut.2018.06.015","volume":"58","author":"LE Simental-Mend\u00eda","year":"2019","unstructured":"Simental-Mend\u00eda LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind, placebo-controlled trial. Nutrition. 2019;58:7\u201310.","journal-title":"Nutrition"},{"issue":"1","key":"2637_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-1198-x","volume":"19","author":"M Akbari","year":"2020","unstructured":"Akbari M, Tamtaji OR, Lankarani KB, Tabrizi R, Dadgostar E, Haghighat N, et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):1\u201312.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"2637_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10741-011-9260-4","volume":"17","author":"H Wang","year":"2012","unstructured":"Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, Li JJ. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev. 2012;17(3):437\u201348.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"2637_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/10408363.2017.1343274","volume":"54","author":"E Abbasi Oshaghi","year":"2017","unstructured":"Abbasi Oshaghi E, Goodarzi MT, Higgins V, Adeli K. Role of resveratrol in the management of insulin resistance and related conditions: mechanism of action. Crit Rev Clin Lab Sci. 2017;54(4):267\u201393.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"10","key":"2637_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1753-4887.2008.00109.x","volume":"66","author":"MD Knutson","year":"2008","unstructured":"Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev. 2008;66(10):591\u20136.","journal-title":"Nutr Rev"},{"issue":"6","key":"2637_CR49","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1002\/ptr.7031","volume":"35","author":"O Toupchian","year":"2021","unstructured":"Toupchian O, Abdollahi S, Salehi-Abargouei A, Heshmati J, Clark CCT, Sheikhha MH, et al. The effects of resveratrol supplementation on PPAR\u03b1, p16, p53, p21 gene expressions, and sCD163\/sTWEAK ratio in patients with type 2 diabetes mellitus: a double-blind controlled randomized trial. Phyther Res. 2021;35(6):3205\u201313.","journal-title":"Phyther Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02637-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T09:04:58Z","timestamp":1652173498000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02637-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02637-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee of Shahid Sadoughi University of Medical Sciences and Health Services in Yazd, confirmed the study protocol, and approved the written informed consent that obtained from all participants at the beginning of the study (IR.SSU.SPH.REC.1396.120).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}